Human Respiratory Syncytial Virus Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Human Respiratory Syncytial Virus Treatment Market is expected to register a CAGR of 10% during the forecast period attributing to increasing prevalence of human respiratory syncytial virus infections and advances in technology. The human respiratory syncytial virus infects the lungs and causes chronic respiratory tract infections, asthma, and bronchiolitis. As per the World Health Organization (WHO), respiratory syncytial is the second largest cause of death in children under one year of age. In addition, in 2017 approximately 33 million people experienced serious respiratory infections. This can be attributed to fewer therapeutics options available for preventing or treating the diseases, thus promoting the growth of the human respiratory syncytial virus treatment market.

Key Market Trends

Based on Human Respiratory Syncytial Virus Treatment Market, Supportive Care is Expected to Witness a Healthy Growth in Future

Supportive care is expected to witness healthy growth in the future. Supportive care is the first line of therapy. Over the counter drugs such as acetaminophen are used for treating the patients. Increasing prevalence of human respiratory syncytial virus (RSV) worldwide is leading to promote the segment growth. Treatment of RSV in supportive care includes oxygen and fluid management wherein nasal suctions and lubrications are given for nasal congestion antipyretics for fever. As this disease is very common in children of two years of age and supportive care is the mainstay treatment of respiratory syncytial virus, which is resulting in the growth of the segment.

North America is Expected to Hold a largest Share in the Market and Expected to do Same in the Forecast Period

North America is at the forefront of growth in the region and is also an important revenue contributor in the global arena. Increasing patient pool with increasing incidences of viral infections among infants in this region are stimulating the growth of the region. As per the National Institute of Allergy and Infectious Diseases (NIAID), in the United States, the majority of children become infected with Respiratory Syncytial virus by age 2 with 75000 to 125000 of them hospitalized every year. Moreover, increasing healthcare expenditure and the presence of well-established healthcare infrastructure is projected to promote revenue growth in North America.

Competitive Landscape

The Human Respiratory Syncytial Virus Treatment Market is fragmented competitive and consists of several major players. Some of the companies which are currently dominating the market are AstraZeneca, F. Hoffmann-La Roche Ltd, AbbVie Inc, ReViral Ltd., Aurobindo Pharma, Zydus Pharmaceuticals, Merck & Co, and Bausch Health.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support